- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
NCCN Congress: Hematologic Malignancies | Conferences
Standard of Care in Newly Diagnosed Myeloma
October 19, 2021
Shaji Kumar, MD, a hematologist at the Mayo Clinic and chair of the Plasma Cell Disorders Scientific Committee at the American Society of Hematology, discuses the standard of care in newly diagnosed myeloma.
Treating Post-MPN Acute Leukemia Remains an Unmet Medical Need
October 18, 2021
In an interview with Targeted Oncology, Gabriela Hobbs, MD discussed the current treatment landscape for MPNs and the research that is aiming to address post-MPN acute leukemia and unmet needs for the patient population.
Improving Risk/Benefit of Frontline Classical Hodgkin Lymphoma Treatment
October 17, 2021
Many options exist for advanced stage cHL, with varying degrees of toxicity. Ranjana H. Advani, MD, gives an overview of each during a presentation at the NCCN 2021 Virtual Congress: Hematologic Malignancies.
Utility of MRD Testing Shown for Select CLL Treatment Regimens
October 16, 2021
The future of minimal residual disease testing in chronic lymphocytic leukemia may be applicable for patients being treated with venetoclax in combination with Bruton’s tyrosine kinase inhibitors.
Treatment Paradigm for R/R Multiple Myeloma Continues to Expand
October 15, 2021
During the NCCN 2021 Congress: Hematologic Malignancies Natalie S. Callander, MD, discusses treatment options in relapsed/refractory multiple myeloma.
Expert Discusses Need for a More Targeted Approach in Acute Myeloid Leukemia
October 15, 2021
In an interview with Targeted Oncology, Alice S. Mims, MD, discussed targeting biomarkers in acute myeloid leukemia, and upfront disease management.
Integrating Prognostic Risk Score into the Diagnosis and Treatment of Patients With MPNs
October 15, 2021
During the NCCN 2021 Congress: Hematologic Malignancies, Aaron T. Gerds, MD, MS, explained the risk stratification tools used in patients with myeloproliferative neoplasms.
Genetic Testing for Actionable Mutations in Newly-Diagnosed AML
October 15, 2021
Alice S. Mims, MD a hematologist at The Ohio State University Comprehensive Cancer Center, discusses testing and actionable mutations in newly diagnosed acute myeloid leukemia.
Optimal Strategies for Treatment of Multiple Myeloma in Newly Diagnosed Patients
October 11, 2020
During a presentation at the National Comprehensive Cancer Institute 2020 Virtual Congress: Hematologic Malignancies, Shaji K. Kumar, MD, explained that each case of multiple myeloma requires a long-term strategy that starts with a strong approach in the frontline setting.
Treatment Options Expand Beyond JAK Inhibition for Patients With Myelofibrosis
October 11, 2020
During the National Comprehensive Cancer Network 2020 Virtual Congress: Hematologic Malignancies, Aaron Gerds, MD, MS, reviewed the current treatment landscape for patients with myelofibrosis and what’s to come for the treatment of this patient population as clinical trials continue to advance the field.